Rapid Rhythm Ltd, a Manchester, UK-based company that has invented a device to help diagnose Atrial Fibrillation (AF), has secured a £50k investment from The North West Fund for Biomedical.
The company intends to use the capital to develop its hand-held device that uses Electro Cardio Graph (ECG) data to diagnose Atrial Fibrillation (AF), a heart condition affecting up to half a million people in the UK. This round of investment will be used to further optimize the design of the device through refining the electrode interfaces to help improve the accuracy of AF diagnosis.
Rapid Rhythm, a spin-out from the Central Manchester University Hospitals NHS Foundation Trust, in collaboration with TRUSTECH Smart Healthcare Ventures, will be also able to make prototypes, run trials and gather data needed to get the device approved.
Consultant cardiologist Dr Adam Fitzpatrick is the inventor of the device.